How Does D-Amino Acid Insertion Shape Protease Resistance in Antimicrobial Peptide Development?

Fmoc-D-phenylalanine is incorporated into synthetic antimicrobial peptide candidates to replace L-Phe or L-Tyr in selected hydrophobic positions. On Rink Amide AM resin with substitution between 0.40 mmol/g and 0.55 mmol/g, the D-Phe residue is coupled at 2.5 equivalents using 2.5 equivalents of OxymaPure and 2.5 equivalents of DIC in DMF at 25 °C for 45 min. The lower excess relative to conventional 3.0-equivalent protocols is applied when D-Phe is installed adjacent to a β-branched residue to reduce reagent accumulation and potential epimerization. After Fmoc removal with 20% piperidine in DMF for 5 min, the resin is washed with six resin-bed volumes of DMF followed by six resin-bed volumes of dichloromethane until the UV baseline at 254 nm returns below 2 mAU. Cleavage from the resin is performed with TFA/triisopropylsilane/water at 95:2.5:2.5 for 2 h. Crude linear peptides are precipitated in cold diethyl ether and analyzed by C18 HPLC at 215 nm; target purity for assay candidates is ≥ 95.0%. Peptide identity is confirmed by ESI-MS with a mass error within ±0.5 Da. For stability screening, the D-Phe-containing peptide is incubated in 25% human serum at 37 °C for 24 h, and intact peptide is quantified by LC-MS at defined time points. The terminal products are linear α-helical antimicrobial peptide leads in which D-Phe substitution at position 4 or position 6 reduces degradation by trypsin-like and chymotrypsin-like proteases. Microbiological evaluation is conducted according to CLSI M07-A10 broth microdilution. D-Phe insertion is accepted only when the minimum inhibitory concentration against reference strains is not increased more than 2-fold relative to the L-Phe comparator. This application is limited to preclinical discovery and early lead optimization because the free carboxylic acid form of Fmoc-D-Phe is consumed as a protected monomer and cannot be used directly as a drug substance.

In automated solid-phase peptide synthesis, Fmoc-D-phenylalanine is charged as a 0.4 M solution in anhydrous DMF. The solution is maintained at 21–25 °C because feed-line precipitation can occur below 15 °C. For first-position coupling onto a 2-chlorotrityl chloride handle, resin substitution is set at 0.45 mmol/g to 0.65 mmol/g, and Fmoc-D-Phe is loaded using 1.5 equivalents of DIEA in dichloromethane for 60 min. Free hydroxyl groups are capped with methanol for 30 min. During chain assembly, each coupling uses 3.0 equivalents of Fmoc-D-Phe relative to resin substitution, preactivated with 2.9 equivalents of HBTU and 6.0 equivalents of DIEA in DMF for 3–5 min before transfer. Single coupling is maintained for 60–90 min at 25 °C. N-terminal Fmoc removal is performed with 20% v/v piperidine in DMF for two cycles of 5 min under nitrogen. The deprotection solution is monitored by UV absorbance at 304 nm. At 0.2 mol synthesis scale, incomplete coupling at sterically hindered sites is corrected by double coupling with 10 min preactivation and 40 min reaction. The assembled peptide resin is washed with DMF, DCM, and methanol, then dried under vacuum at 30 °C for 8 h. Cleavage uses TFA/triisopropylsilane/water at 95:2.5:2.5 for 2 h, followed by precipitation in cold MTBE at −20 °C. Preparative reversed-phase C18 chromatography with acetonitrile/water containing 0.1% TFA removes deletion and diastereomer impurities; the counterion is exchanged to acetate using ion-exchange resin. The product class is D-Phe-containing macrocyclic peptide drug substance, including octreotide-type somatostatin receptor ligands with a D-Phe residue at position 1. For GMP batches, Fmoc-D-Phe is controlled as a critical starting material under ICH Q7; residual solvents in the final peptide are tested per USP 467, and the peptide drug substance analytical panel is executed under 21 CFR 211.160. Release of Fmoc-D-Phe in this application requires assay ≥ 98.5% area by HPLC at 254 nm, L-phenylalanine contamination ≤ 0.5% by chiral HPLC, moisture ≤ 0.5% by Karl Fischer titration, and specific optical rotation within the manufacturer’s certified range. The acid-labile Fmoc group is stable during neutral coupling but undergoes premature cleavage in feed streams that contain residual piperidine above 100 ppm. Pre-drying of DMF over 4A molecular sieves is performed when ambient relative humidity exceeds 60% to prevent hydrolysis of activated carboxyl groups.

Cyclic pentapeptides incorporating the Arg-Gly-Asp motif are assembled with Fmoc-D-phenylalanine as the D-Phe residue in the c(RGDfK) sequence. In this configuration, Fmoc-D-Phe is loaded as the C-terminal residue onto 2-chlorotrityl chloride resin at a substitution of 0.70 mmol/g to 0.85 mmol/g using 1.5 equivalents of DIEA in dichloromethane for 60 min. The remaining peptide chain is assembled with 3.0 equivalents of Fmoc-protected amino acids and HATU/DIEA activation. After linear assembly, the Fmoc group is removed and the side-chain-protected peptide is cleaved from the resin with 20% hexafluoroisopropanol in dichloromethane for 30 min at 25 °C. The filtered solution is concentrated at 25 °C and precipitated in cold n-heptane. Head-to-tail cyclization is performed in DMF at a peptide concentration of 1 mM using 1.1 equivalents of diphenylphosphoryl azide and 3.0 equivalents of DIEA at 4 °C for 18 h. Cyclization conversion is monitored by C18 HPLC; target conversion before workup is ≥ 85%. The crude cyclic peptide is treated with TFA/triisopropylsilane/water at 95:2.5:2.5 for 2 h to remove side-chain protecting groups. Preparative C18 HPLC with acetonitrile/water containing 0.1% TFA yields c(RGDfK) with purity ≥ 97.0% at 220 nm and ESI-MS mass within ±0.5 Da of the calculated monoisotopic mass. This D-Phe-containing cyclic pentapeptide is used as an integrin αvβ3-binding vector for conjugation to chelators for ⁶⁸Ga PET or ¹⁷⁷Lu therapy. Residual solvent levels are controlled per USP 467, and residual TFA is measured by ion chromatography; acceptance is ≤ 0.1% in the lyophilized product. The stereochemical integrity of D-Phe in the final cyclic peptide is confirmed by amino acid analysis of the acid hydrolysate using chiral derivatization and GC-MS; L-Phe in the hydrolysate is controlled below 1.0 mol% because diastereomer contamination alters integrin binding.

When Fmoc-D-Phenylalanine Is Coupled at the C-Terminal Dimer Position, Diketopiperazine Formation Becomes the Controlling Variable

The most destructive processing window in Fmoc-D-Phe chain assembly occurs after coupling to a C-terminal Gly or Pro residue on a 2-chlorotrityl chloride linker. Once the dipeptide Fmoc-D-Phe-Gly-O-2-chlorotrityl resin is formed, standard piperidine deprotection of the Fmoc group releases a free amine at the D-Phe terminus. That amine can attack the ester bond between Gly and the acid-labile resin, forming cyclo(D-Phe-Gly) and releasing the dipeptide from the support. The same diketopiperazine pathway occurs with Fmoc-D-Phe-Pro-O-2-chlorotrityl resin and is accelerated at 25 °C in DMF. Resin mass loss in such cases is monitored gravimetrically after washing with DMF and DCM; losses greater than 5% by mass before final cleavage indicate diketopiperazine-mediated chain truncation. In a 20 mL solid-phase synthesis vessel with sintered frit and overhead stirring at 150 rpm, 20% piperidine in DMF for 2 × 10 min is replaced by a single 1% DBU in DMF treatment for 3 min when the D-Phe residue is directly attached to Pro or Gly. Where DBU cannot be used due to downstream racemization sensitivity, the deprotection temperature is lowered to 4 °C and piperidine contact is limited to 5 min. Published data for this specific configuration is limited; confirmation by cleavage sample mass balance and C18 HPLC of the released diketopiperazine fraction is required. The solid support and linker are also changed to Wang resin in sequences where the C-terminal dimer contains D-Phe and the final peptide is to be a protected fragment for solution-phase coupling. After optimized deprotection, the remaining chain is elongated using double coupling with 3.0 equivalents of Fmoc-D-Phe and 3.0 equivalents of HATU at 25 °C. The final cleaved product is screened for deletion peptide contaminants using LC-MS; the acceptance limit for des-D-Phe analogue is ≤ 0.2% area at 215 nm in the peptide drug substance. This diketopiperazine-sensitive condition restricts the use of 2-chlorotrityl chloride resin for D-Phe-containing peptides intended for cGMP manufacture when process reproducibility across multiple production lots cannot be demonstrated.

For analytical reference standard preparation in peptide drug substance impurity profiling, Fmoc-D-phenylalanine is used to synthesize peptide fragments containing D-Phe and their L-Phe diastereomer counterparts. The assembly is performed on a 25 µmol scale in a 10 mL solid-phase synthesis vessel using Rink Amide MBHA resin with substitution at 0.35 mmol/g. Coupling of Fmoc-D-Phe is carried out with 3.0 equivalents of amino acid, 3.0 equivalents of HOBt, and 3.0 equivalents of DIC in DMF for 60 min. Deprotection uses 20% piperidine in DMF for 2 × 5 min. Cleavage with TFA/triisopropylsilane/water at 95:2.5:2.5 for 2 h yields the crude peptide standard. Purification is performed by semi-preparative C18 HPLC with acetonitrile/water and 0.1% TFA; target purity is ≥ 98.0% area at 215 nm. The purified standard is lyophilized and assigned a peptide content value by mass balance using HPLC, Karl Fischer titration per USP 921, and residual solvent analysis per USP 467. This standard is used in method validation under ICH Q2(R1) to establish specificity, linearity, accuracy, and limit of detection for the diastereomer impurity assay of the parent peptide drug substance. For a D-Phe-containing peptide API, the L-Phe diastereomer is the principal stereochemical impurity; its quantification in release and stability studies is performed using a chiral or reversed-phase HPLC method with acceptance limits justified under ICH Q3A. Fmoc-D-Phe specifically enables the independent synthesis of the stereochemically defined impurity with high optical purity; L-Phe contamination in the purified marker is controlled below 0.5% by chiral HPLC. This application operates at low scale and does not require the high-loading process conditions used in therapeutic peptide manufacturing.

High-throughput peptide library construction for D-amino acid positional scanning uses Fmoc-D-phenylalanine as a protected monomer in 96-well resin arrays. A stock solution of 0.3 M Fmoc-D-Phe in NMP is prepared fresh daily and filtered through a 0.45 µm PTFE membrane before transfer to a liquid handler. In each well, 25 mg of Rink Amide ChemMatrix resin with substitution at 0.45 mmol/g is swollen in DMF for 30 min. The automated cycle dispenses 4.0 equivalents of Fmoc-D-Phe, 4.0 equivalents of HATU, and 8.0 equivalents of DIEA in a total volume of 0.15 mL per well. Coupling proceeds at 25 °C for 40 min with orbital shaking at 800 rpm. Between coupling steps, the wells are drained and washed with DMF and dichloromethane; wash volumes are 0.20 mL per well for six cycles. Fmoc removal uses 20% piperidine in DMF for 5 min followed by UV monitoring of the combined deprotection solution at 304 nm to verify coupling efficiency. Cleavage from parallel plates uses 0.10 mL of TFA/triisopropylsilane/water at 95:2.5:2.5 per well for 2 h at 25 °C. The cleavage cocktail is evaporated under a nitrogen flow at 35 °C, and the crude peptides are precipitated in cold diethyl ether. The resulting library members are analyzed in pools by LC-MS; individual wells with target mass below 60% of expected are excluded from primary screening. This platform application produces diverse D-Phe-containing peptide libraries used for cellular receptor binding and protease stability screening. The use of Fmoc-D-Phe in parallel synthesis is constrained by the slower coupling rate of D-amino acids in NMP compared with DMF; therefore reaction times are extended by 50% relative to L-amino acid standards. Operational failure occurs if a preactivation mixture containing HATU and Fmoc-D-Phe is kept beyond 8 h at 25 °C, because activated esters hydrolyze in residual water from the solvent.